Screener
BioMarin Pharmaceuticals BMRN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $1,005,793 | $759,031 |
| Current portion of long-term debt, net | 658,203 | — |
| Total current liabilities | 1,663,996 | 759,031 |
| Noncurrent liabilities: | ||
| Long-term debt, net | 3,527,939 | 597,176 |
| Other long-term liabilities | 209,815 | 150,816 |
| Total liabilities | 5,401,750 | 1,507,023 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's total current liabilities?
- BioMarin Pharmaceuticals (BMRN) reported total current liabilities of $1.66B in Q2 2026.
- How has BioMarin Pharmaceuticals's total current liabilities changed year-over-year?
- BioMarin Pharmaceuticals's total current liabilities increased by 143.2% year-over-year, from $684.25M to $1.66B.
- What is the long-term trend for BioMarin Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total current liabilities has grown at a 9.0% compound annual growth rate (CAGR), from $492.55M to $759.03M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about BioMarin Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude